Literature DB >> 19385998

Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.

Ana Teresa Pinto e Silva1, Sofia Costa-de-Oliveira, Ana Silva-Dias, Cidália Pina-Vaz, Acácio Gonçalves Rodrigues.   

Abstract

Candida parapsilosis is a common isolate from clinical fungal infectious episodes. Resistance of C. parapsilosis to azoles has been increasingly reported. To analyse the development of resistance in C. parapsilosis, four azole-susceptible clinical strains and one American Type Culture Collection type strain were cultured in the presence of fluconazole, voriconazole and posaconazole at different concentrations. The isolates developed variable degrees of azole resistance according to the antifungal used. Fluconazole was the fastest inducer while posaconazole was the slowest. Fluconazole and voriconazole induced resistance to themselves and each other, but not to posaconazole. Posaconazole induced resistance to all azoles. Developed resistance was stable; it could be confirmed after 30 days of subculture in drug-free medium. Azole-resistant isolates revealed a homogeneous population structure; the role of azole transporter efflux pumps was minor after evaluation by microdilution and cytometric assays with efflux pump blockers (verapamil, ibuprofen and carbonyl cyanide 3-chloro-phenylhydrazone). We conclude that the rapid development of azole resistance occurs by a mechanism that might involve mutation of genes responsible for ergosterol biosynthesis pathway, stressed by exposure to antifungals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19385998     DOI: 10.1111/j.1567-1364.2009.00508.x

Source DB:  PubMed          Journal:  FEMS Yeast Res        ISSN: 1567-1356            Impact factor:   2.796


  13 in total

1.  The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.

Authors:  Themistoklis K Kourkoumpetis; George C Velmahos; Panayiotis D Ziakas; Emmanouil Tampakakis; Dimitra Manolakaki; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2010-10-08       Impact factor: 2.574

2.  Transcriptional profiling of azole-resistant Candida parapsilosis strains.

Authors:  A P Silva; I M Miranda; A Guida; J Synnott; R Rocha; R Silva; A Amorim; C Pina-Vaz; G Butler; A G Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

3.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

4.  Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.

Authors:  Chiung-Kuang Chen; Siegfried S F Leung; Christophe Guilbert; Matthew P Jacobson; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2010-04-06

5.  A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Authors:  Patricia S Doyle; Chiung-Kuang Chen; Jonathan B Johnston; Stephanie D Hopkins; Siegfried S F Leung; Matthew P Jacobson; Juan C Engel; James H McKerrow; Larissa M Podust
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

6.  Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives.

Authors:  Debora F Vieira; Jun Yong Choi; William R Roush; Larissa M Podust
Journal:  Chembiochem       Date:  2014-04-25       Impact factor: 3.164

7.  Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.

Authors:  Ana P Silva; Isabel M Miranda; Carmen Lisboa; Cidália Pina-Vaz; Acácio G Rodrigues
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

8.  Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.

Authors:  Cecília Rocha da Silva; João Batista de Andrade Neto; José Júlio Costa Sidrim; Maria Rozzelê Ferreira Angelo; Hemerson Iury Ferreira Magalhães; Bruno Coêlho Cavalcanti; Raimunda Sâmia Nogueira Brilhante; Danielle Silveira Macedo; Manoel Odorico de Moraes; Marina Duarte Pinto Lobo; Thalles Barbosa Grangeiro; Hélio Vitoriano Nobre Júnior
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

9.  Fluconazole and Voriconazole Resistance in Candida parapsilosis Is Conferred by Gain-of-Function Mutations in MRR1 Transcription Factor Gene.

Authors:  Joana Branco; Ana P Silva; Raquel M Silva; Ana Silva-Dias; Cidália Pina-Vaz; Geraldine Butler; Acácio G Rodrigues; Isabel M Miranda
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

10.  Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51.

Authors:  Shamila S Gunatilleke; Claudia M Calvet; Jonathan B Johnston; Chiung-Kuang Chen; Grigori Erenburg; Jiri Gut; Juan C Engel; Kenny K H Ang; Joseph Mulvaney; Steven Chen; Michelle R Arkin; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.